Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03582436
Other study ID # K170909J
Secondary ID 2018-A00090-55
Status Completed
Phase
First received
Last updated
Start date June 25, 2018
Est. completion date March 18, 2021

Study information

Verified date February 2022
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Main objective: To constitute a prospective multicentre French cohort of kidney transplant recipients including clinical, biological and immunological evaluation combined with non-invasive biomarkers in peripheral blood and urine, and gene expression assessment in allograft biopsy in order to increase the performance of rejection diagnosis in kidney transplant patients. the investigators hypothesise that the addition of non-invasive biomarkers and intragraft assessment of gene expression profiles will improve the diagnosis capacity of histology in kidney transplant recipients as it reveals pathophysiological pathways that are not captured by light microscopy.


Description:

Rejection currently represents the major cause of allograft failure worldwide, with immediate consequences for the patients in terms of mortality, morbidity and costs for the society. The field of transplantation lacks robust assessments for immune monitoring and diagnoses. Currently, light microscopy still represents the gold standard, which has clearly been identified as imperfect. Given those facts, success of clinical trials is impaired with space for improvement of current diagnosis standards that should eventually lead to improved outcomes for kidney transplant recipients. This study will provide the investigators with prospective data of kidney transplant patient that will allow the improvement of rejection diagnosis and individual immune monitoring for precision medicine: improvement of rejection diagnosis, stage and assessment of response to therapy. In order to estimate for each patient a probability of rejection, The investigators will generate algorithms using traditional clinical, biological and histological data that will be enriched by tissue as well as blood and urine non-invasive immune biomarkers. These algorithms will be encapsulated in a "user-friendly" web-based application with best in-class visualisation : the TransplanScreen will display individual information with comparative and predictive context for clinicians and patients and better interfacing and communication. It will include a comprehensive TransplanScreen report based on the algorithms and included in Electronic Medical Record databases (object-oriented). It aims to provide visual and contextual information to promote personalised decision making, addressing the demand of public health authorities for improving efficiency and quality of care. The expected benefit for participants and society will be to reduce the financial burden of graft rejection for society. The cohort will include n=750 kidney transplant recipients in 8 French centres : 3 Parisian ones: Necker hospital, Saint-Louis Hospital and Bichat hospital and 4 regional ones: CHU Nantes, Toulouse and Bordeaux, Montpellier and Lyon Hospitals. Bichat hospital will not be recruiting but will contribute to the research. Vulnerable participants excluded. Schedule for the study: - inclusion period: 12 months - participation period (treatment - follow-up): 12 months - total duration of the study: 24 months Exclusion period for participation in other studies, and justification: the participation to other minimal risks and constraints studies and observational non-interventional studies is allowed during this study. There is no exclusion period at the end of study. The participation to other interventional and observational non-interventional studies is allowed after the end of the study. Number of enrolments expected per site and per month : - Necker Hospital: 14 patients / month - Saint-Louis Hospital: 8 patients / month - CHU Nantes: 10 patients / month - Lyon Hospitals: 9 patients / month - CHU Toulouse: 13 patients / month - CHU Bordeaux: 9 patients / month. - CHU Montpelier: 8/month


Recruitment information / eligibility

Status Completed
Enrollment 824
Est. completion date March 18, 2021
Est. primary completion date March 18, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Men or female patients, Age = 18 years old at the time of transplantation. Patients receiving a kidney transplant from a living or deceased donor. Patients who signed the informed consent form and willing to comply with study procedures. Female patients of child-bearing potential must have a negative pregnancy test (serum beta-hCG) and must be practicing an effective, reliable and medically approved contraceptive regimen Patients with a minimum weight of 40 kg Exclusion Criteria: History of multi-organ transplant (interference with rejection natural history). Unable/unwilling to comply with study procedures (including foreign language speakers who are not assisted by a native French speaker). Vulnerable participants (minors, protected adults, pregnant women, legally detained

Study Design


Intervention

Procedure:
Kidney transplantation
For the patients with the kidney transplantation, these parameters will be analysis: Transcriptomics analysis Characteristics of anti HLA DSA analysis Non-HLA antibodies analysis Omics blood analysis Urine chemokines analysis

Locations

Country Name City State
France Hopital Saint-Louis Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Concordance of invasive/non-invasive biomarkers with allograft rejection Concordance of invasive/non-invasive biomarkers with allograft rejection diagnosed by the gold standard (histology) in kidney transplant recipients. month 12
Secondary Association of non-invasive biomarkers with different subtypes of rejection Association of non-invasive biomarkers with different subtypes of rejection month 12
Secondary Association of gene sets with different subtypes of rejection in the biopsy. Association of gene sets with different subtypes of rejection in the biopsy. month 12
Secondary Reclassification capacity of gene sets and non-invasive biomarkers to define allograft rejection. Reclassification capacity of gene sets and non-invasive biomarkers to define allograft rejection month 12
Secondary Variation of the non-invasive biomarker signature of allograft rejection ariation of the non-invasive biomarker signature of allograft rejection as a response to the standard of care in kidney transplant recipients. month 12
Secondary Variation of the gene set signature Variation of the gene set signature of allograft rejection from the biopsy as a response to the standard of care in kidney transplant recipients. month 12
Secondary Cumulative incidence of antibody-mediated rejection (ABMR) Cumulative incidence of antibody-mediated rejection (ABMR) that occurs between D0 and M12 (ABMR that meets Banff 2015 criteria) month 12
Secondary Cumulative incidence of T-cell-mediated rejection (TCMR) Cumulative incidence of T-cell-mediated rejection (TCMR) that occurs between D0 and M12 (TCMR that meets Banff 2015 criteria) month 12
Secondary Treatment failure rate Treatment failure rate defined as the occurrence of 1) biopsy proven ABMR and/or TCMR, 2) graft loss, 3) patient death month 12
Secondary Graft and patient survival Graft and patient survival at M6 and M12 post-transplantation month 12
Secondary Histological evidence of ABMR and/or TCMR on protocol biopsies Histological evidence of ABMR and/or TCMR on protocol biopsies without other clinical findings at M3 and M12 post-transplantation month 12
Secondary Overall pathological changes, including chronic ABMR Overall pathological changes, including chronic ABMR, on protocol biopsies M3 and M12 post-transplantation month 12
Secondary Incidence of delayed graft function Incidence of delayed graft function (DGF) post-transplantation month 12
Secondary Cumulative incidence and duration of dialysis. Cumulative incidence and duration of dialysis between 7 days and M12 post- transplantation month 12
See also
  Status Clinical Trial Phase
Recruiting NCT04910867 - APOL1 Genetic Testing Program for Living Donors N/A
Completed NCT02723591 - To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients Phase 4
Completed NCT05945511 - Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
Completed NCT02234349 - Bile Acids and Incretins in Pancreas Kidney Transplant Patients N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Not yet recruiting NCT05934383 - Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension N/A
Withdrawn NCT04936971 - Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response Phase 4
Not yet recruiting NCT04540640 - Oxygenated Machine Preservation in Kidney Transplantation N/A
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Recruiting NCT02908139 - Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients N/A
Completed NCT02560558 - Bela 8 Week Dosing Phase 4
Terminated NCT02417870 - Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation Phase 1/Phase 2
Recruiting NCT02154815 - Pre-emptive Kidney Transplantation Quality of Life N/A
Completed NCT02235571 - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients N/A
Enrolling by invitation NCT01905514 - ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients N/A
Completed NCT02147210 - Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1 N/A
Recruiting NCT01699360 - The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients Phase 4
Completed NCT01672957 - ORANGE Study: An Observational Study on Renal Function in Kidney Transplant Patients on Immunosuppressive Therapy Containing CellCept (Mycophenolate Mofetil) N/A
Completed NCT01655563 - Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation Phase 2